EKF Diagnostics Hldg - Additional Share Buyback Programme

EKF Diagnostics Holdings plc

("EKF" or the "Company")

Additional Share Buyback Programme

EKF Diagnostics Holdings plc (AIM: EKF), the AIM-listed global diagnostics business, announces that following the successful conclusion of the initial share buyback programme, confirmed on 13 May 2025, the Company intends to conduct additional on-market purchases of ordinary shares of 1p each in the Company ("Ordinary Shares") of up to a further c.£1.0m, pursuant to the authorities obtained at the Company's last annual general meeting held on 20 May 2025. Any Ordinary Shares repurchased will be held in treasury.

Christopher Mills, Non-Executive Director of the Company, is the Chief Investment Officer of Harwood Capital Management (Gibraltar) Limited ("Harwood"), which is investment manager to Oryx International Growth Fund Limited ("Oryx") and Chief Investment Officer of North Atlantic Smaller Companies Investment Trust PLC ("NASCIT"). Mr. Mills is a director and shareholder in Oryx and also a director and shareholder in NASCIT. Oryx and NASCIT hold 36,544,396 and 95,088,797 Ordinary Shares, respectively, and 132,433,193 Ordinary Shares in aggregate (with 800,000 Ordinary Shares held by Harwood Capital LLP), which is equivalent to approximately 29.49% of the current total voting rights in the Company. Harwood will facilitate the participation of these entities in the share buy back pro rata to their existing aggregate holding, with the intention that the aggregate indirect beneficial interest of Mr. Mills remains at approximately this level and in any event does not exceed 30.00% of the prevailing total voting rights in the Company following any repurchases. This is solely in order for Mr. Mills and the above connected entities (which are, unless otherwise established, deemed to be acting in concert in accordance with the City Code on Takeovers and Mergers) to avoid otherwise being subject to an obligation under the City Code on Takeovers and Mergers to make a mandatory offer for the Company's entire share capital or to obtain the requisite shareholder approval for a waiver from the Takeover Panel from such obligation.

This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014 (which forms part of domestic UK law pursuant to the European Union (Withdrawal) Act 2018). 

The person responsible for arranging the release of this Announcement
on behalf of the Company is Julian Baines, Executive Chair.

About EKF Diagnostics Holdings plc (www.ekfdiagnostics.com)

EKF is an AIM-listed global diagnostics business focussed on:

EKF has headquarters in Penarth (near Cardiff) and operates five manufacturing sites across the US and Germany, selling into over 120 countries world-wide.